# Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

> **NCT00358319** · PHASE1,PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 42 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Karenitecin
- **DRUG:** Valproic Acid

## Key facts

- **NCT ID:** NCT00358319
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** PI left Moffitt
- **Last updated:** 2013-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358319, "Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00358319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*